News

Check out the pipeline updates from February!

Learn more about the 5 principles of intervention that serve as guidance for developing practices after disasters and mass violence.

Remembering Alvin F. Poussaint, MD…

Newly shared top-line phase 4 data demonstrates clinically meaningful and sustained effects of Ingrezza capsules on the physical, social, and emotional impacts experienced with tardive dyskinesia.

A recent meta-analysis compares efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for adults with ADHD.

The relationship between social media use and mental health remains inconclusive. How can you best treat child and adolescents and guide their social media use?

Can AI innovations assist in the process of creating the next DSM? One psychiatrist explains his thoughts.

"Connect me to all children, Under undue distress all ‘round the world, Shaping the future of our warring lands..."

How should clinicians approach treatment when their patient disagrees with the diagnosis?

According to research, symptoms of ADHD are more often overlooked or diagnosed later in children with higher cognitive ability, physical activity, or social skills.

Learn how best to facilitate catatonia assessment via telepsychiatry in this 3-case example article.

Could social media offer a new approach for clinicians working with patients experiencing some phobias?

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

How one resident found a free and accessible way to cope with her arachnophobia.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

The fact that celiac disease has effects on the brain is recognized but not completely understood.

Why are older patients turning to cannabis for symptom relief?

At least 300 to 400 physicians a year die by suicide in the United States. Learn more about the latest statistics.

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.

Learn more about how to appropriately diagnose and categorize a spectrum of posttraumatic stress responses in children and adolescents.

“Give me your tired, your poor, your huddled masses yearning to breathe free…”

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

How has the field of child and adolescent psychiatry matured over the last 3 decades? Our Special Report Chair, Peter S. Jensen, MD, elaborates.

How can you provide comprehensive care in underserved environments, particularly for individuals with complex mental health needs? Amitha Dhingra, MD, weighs in.

What can psychiatry learn from a podcast about grief?

"Make America Healthy Again” has taken a jab at psychiatry.

Antipsychiatry’s animus toward psychiatric medication has both ancient and modern parallels.

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.